Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

The owner of Wegovy and Ozempic has suffered a significant setback, as its highly anticipated new weight-loss treatment was labelled “obsolete” after disappointing clinical trials.

Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.

Continue reading…

Published by Archie Watson on 23 February 2026. GEMHerald summarises reporting from other outlets and links to the original. Read our editorial policy and how we handle corrections.